Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04881682 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Study acronym: IVITOC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Mar 1, 2026 to Sep 1, 2027
    • Study completion date: Mar 1, 2026 to Mar 1, 2028
    v6
  2. Re-verified, no change to tracked fieldsv5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Jun 1, 2024 to Mar 1, 2026
    • Start date changed from estimate of Jan 1, 2023 to May 1, 2023
    • Site details revised
    v4
  4. Start date: Jan 1, 2022 to Jan 1, 2023v3
  5. Primary and study completion dates: Oct 1, 2023 to Jun 1, 2024
    • Start date: Jun 1, 2021 to Jan 1, 2022
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Trial Details
NCT Number NCT04881682
Lead Sponsor University of Ulm
Collaborators: Miltenyi Biomedicine GmbH
Conditions
(from sponsor)		 CIDP
Related terms Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov